摘要
背景与目的:CA-125已经是公认的卵巢癌标志物,在长期的临床观察中发现血清CA-125在肺癌诊治中具有一定的诊断及判定预后的价值。本研究探讨中医药治疗术后与不能切除肿瘤的肺癌患者时对血清CA-125的影响;同时探讨血清CA-125与肺癌临床分期及病理学类型相关性。方法:用微粒学酶免分析法检测30例健康人及60例肺癌患者中医综合治疗方案治疗前后血清CA-125水平,并作对比分析。结果:血清CA-125在肺癌患者的值(91±45)与健康人(18±5)相比,差异有非常显著性,(P<0.001),血清CA-125在ⅢA/ⅢB及Ⅳ期肺癌患者中值分别为85±21及142±25,与Ⅰ/Ⅱ期患者的35±11相比,差异有非常显著性(P<0.001)肺腺癌患者CA-125水平(127±31)与鳞癌(58±27)及小细胞癌(56±26)相比,差异有非常显著性(P<0.001)。ⅢA/ⅢB及Ⅳ期肺癌患者中医药综合治疗方案治疗后CA-125值分别为(36±11;87±15)于治疗前(85±21;142±25)相比,差异有非常显著性.(P<0.001)。但对于Ⅰ/Ⅱ期患者治疗后(33±10)与治疗前(35±11)相比,差异无显著性(P>0.05)。结论:中医药治疗肺癌,在Ш/Ⅳ期的肺癌患者可显著的降低血清CA-125水平,在Ⅰ/Ⅱ期的肺癌患者也有明显的降低血清CA-125水平的趋势。血清CA-125水平与肺癌患者临床分期、病理类型有关。
Background and purpose： CA-125 is already recognized as one of the biomarkers for ovarian cancer. The serum CA-125 alsn had some significance in terms of the diagnosis and determination of the prognostie values for lung cancer. The purpose of this study was to investigate the effect of traditional Chinese medicine （TCM） therapy on serum CA-125 level in lung eancer patients. At the stone time, we investigated the relationship between the serum CA-125 level and the clinical stages as well as the pathological types. Methods： Serum CA-125 levels from 30 normlal donors were detected and compared to 60 patients with lung cancer by mieroparticle enzyme inmmnosorbant assay （MEIA）. Results： Serum CA-125 levels in lung cancer group were （91±45） and significantly higher than those in healthy control group（ 18±5） （P 〈 0.001）. For TNM stage, serum CA-125 levels in ⅢA/ⅢB was （85±21） and （142 ±25） in Ⅳ stage, they were significantly different from those in Ⅰ/Ⅱ （ 35 ± 11 ） stage（ P 〈 0. 001）. For histology, serum CA-125 levels in the patients with adenoearcinoma was （ 127 ±31） and statistically higher than those with squamous cell carcinoma（58 ±27） and small cell carcinoma（56 ± 26） （ P 〈 0.001 ）. Traditional Chinese medicine eouhl decrease serum CA-125 levels in the patients with ⅢA/ⅢB and Ⅳ stage, there were significant differences between before and after treatment[ （ 36 ± 11 ; 87±15） vs. （ 85 ± 21 ; 142 ± 25） ] （ P 〈0.001 ）., hut not in the patients with Ⅰ/ Ⅱ stage. Conclusions： TCM therapy can significantly decrease serum CA-125 level in Ⅲ/Ⅳ stage lung cancer patients, and also has a marked tendeneey to decrease the serum CA-125 level in Ⅰ/ Ⅱ stage lung cancer patients. Serum CA-125 level may be closely related to clinical TNM stages and pathnlogical types.
出处
《中国癌症杂志》
CAS
CSCD
2008年第2期110-112,共3页
China Oncology
基金
上海市重点学科资助(Y0302)
